Integrated therapy including acupuncture in a patient with long-term survival from spinal cord metastases of ALK-positive lung adenocarcinoma: a case report - Top-Institutions - MDSpire

Integrated therapy including acupuncture in a patient with long-term survival from spinal cord metastases of ALK-positive lung adenocarcinoma: a case report

  • By

  • Xiaojun Zhang

  • Guoping Ye

  • Wenzhen Chen

  • Jianwen Luo

  • Xiaoli Wu

  • June 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Integrative Medicine

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Integrative Medicine

  • #3

    Zhongnan Hospital of Wuhan University
    Zhongnan Hospital of Wuhan University

    Wuhan, Hubei

    Key Differentiators

    • Oncology

  • #4

    Affiliated Hospital of Jiangsu University
    Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu

    Key Differentiators

    • Oncology

  • #5

    Peking Union Medical College Hospital
    Peking Union Medical College Hospital

    Beijing, Beijing

    Key Differentiators

    • Oncology

Original Source(s)

Integrated therapy including acupuncture in a patient with long-term survival from spinal cord metastases of ALK-positive lung adenocarcinoma: a case report

  • by Xiaojun Zhang, Guoping Ye, Wenzhen Chen, Jianwen Luo, Xiaoli Wu

  • June 23, 2026

Related Content

Endocrine-driven inflammatory–epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis

Identification and validation of biomarkers related to mismatch repair for prognosis prediction in glioma

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells